NCT01154933View on ClinicalTrials.gov

Exeantide in Type 2 Diabetes on Insulin

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Type 2 Diabetes
Interventions
DRUG

exenatide 5 mcg

exenatide 5 mcg

DRUG

exenatide 10 mcg

exenatide 10 mcg

DRUG

placebo

saline sq

Trial Locations (1)

14209

Millard Fillmore Gates Hospital, Buffalo

Sponsors
All Listed Sponsors
collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

lead

University at Buffalo

OTHER